FUJIFILM Cellular Dynamics, specializing in human induced pluripotent stem cells (iPSC) and iPSC-derived cells, and FUJIFILM Diosynth Biotechnologies in California, a prominent CDMO in biologics and advanced therapies, will be the main beneficiaries.
The investment aims to strengthen manufacturing capacity for, various cell therapies including iPSC-derived cell therapies, Cytoxic T-lymphocyte (CTL), Chimeric Antigen Receptor (CAR), T-cell Receptor (TCR), Natural Killer (NK), and tissue-derived therapies.
Cell therapies present significant potential for augmenting, repairing, or replacing human biology, with more than 500 ongoing global clinical trials in this field.
FUJIFILM Cellular Dynamics will use the investment to build a new 175,000 sq. ft headquarters in Madison, Wisconsin, USA, doubling existing manufacturing capacity for iPSC-derived cell therapies.
The expanded site will also cater to iPSC manufacturing for research and development applications in drug discovery, drug efficacy, and pharmacology.
In California, FUJIFILM Diosynth Biotechnologies will expand its site with a development lab and two new independent manufacturing clean rooms, significantly increasing production capacity for new client programs.
The added capacity is expected to be operational in early 2025, enhancing expertise in clinical and commercial manufacturing of in vitro cell lines for various cell therapies.
The facility will include iPSC cGMP manufacturing, process development laboratories, warehouse operations, and administrative space, operational by spring 2026.